Morgan Stanley analyst Michael Cyprys maintains Nasdaq (NASDAQ:NDAQ) with a Overweight and raises the price target from $67 to $68.
Tale Of Two Investigational Obesity Drugs: Altimmune Stock Jumps, While Pfizer Trades Lower
Altimmune Inc (NASDAQ: ALT) announced topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide